PMID- 31333661
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20201022
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 10
DP  - 2019
TI  - Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses.
PG  - 1529
LID - 10.3389/fimmu.2019.01529 [doi]
LID - 1529
AB  - Dendritic cells (DCs) facilitate cross talk between the innate and adaptive 
      immune system. They sense and phagocytose invading pathogens, and are not only 
      capable of activating naive T cells, but can also determine the polarization of T 
      cell responses into different effector subtypes. Polarized T cells in turn have a 
      crucial role in antibody class switching and affinity maturation, and 
      consequently the quality of the resulting humoral immunity. Targeting vaccines to 
      DCs thus provides a great deal of opportunities for influencing the humoral 
      immune responses, by fine-tuning the T cell response as well as regulating 
      antigen availability for B cells. In this review we aim to outline how different 
      DC targeted vaccination strategies can be utilized to induce a desired humoral 
      immune response. A range of factors, including route of vaccine administration, 
      use of adjuvants, choice of DC subset and surface receptor to target have been 
      reported to influence the resulting immune response and will be reviewed herein. 
      Finally, we will discuss opportunities for designing improved vaccines and 
      challenges with translating this knowledge into clinical or veterinary medicine.
FAU - Tesfaye, Demo Yemane
AU  - Tesfaye DY
AD  - K. G. Jebsen Center for Research on Influenza Vaccines, Oslo University Hospital, 
      University of Oslo, Oslo, Norway.
AD  - Department of Immunology and Transfusion Medicine, Oslo University Hospital, 
      Oslo, Norway.
FAU - Gudjonsson, Arnar
AU  - Gudjonsson A
AD  - K. G. Jebsen Center for Research on Influenza Vaccines, Oslo University Hospital, 
      University of Oslo, Oslo, Norway.
AD  - Institute of Clinical Medicine, Oslo University Hospital, University of Oslo, 
      Oslo, Norway.
FAU - Bogen, Bjarne
AU  - Bogen B
AD  - K. G. Jebsen Center for Research on Influenza Vaccines, Oslo University Hospital, 
      University of Oslo, Oslo, Norway.
AD  - Department of Immunology and Transfusion Medicine, Oslo University Hospital, 
      Oslo, Norway.
AD  - Institute of Clinical Medicine, Oslo University Hospital, University of Oslo, 
      Oslo, Norway.
FAU - Fossum, Even
AU  - Fossum E
AD  - K. G. Jebsen Center for Research on Influenza Vaccines, Oslo University Hospital, 
      University of Oslo, Oslo, Norway.
AD  - Department of Immunology and Transfusion Medicine, Oslo University Hospital, 
      Oslo, Norway.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190704
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Vaccines)
SB  - IM
MH  - Animals
MH  - Antibody Formation/*drug effects
MH  - B-Lymphocytes/immunology
MH  - Dendritic Cells/*immunology
MH  - *Drug Delivery Systems
MH  - Gene Rearrangement, B-Lymphocyte/drug effects/immunology
MH  - Humans
MH  - Immunity, Humoral/*drug effects
MH  - T-Lymphocytes/immunology
MH  - *Vaccination
MH  - *Vaccines/immunology/therapeutic use
PMC - PMC6620736
OTO - NOTNLM
OT  - DC subtypes
OT  - Th1 & Th2
OT  - antibody
OT  - dendritic cell (DC)
OT  - targeting
OT  - vaccination
EDAT- 2019/07/25 06:00
MHDA- 2020/10/23 06:00
PMCR- 2019/01/01
CRDT- 2019/07/24 06:00
PHST- 2019/03/29 00:00 [received]
PHST- 2019/06/19 00:00 [accepted]
PHST- 2019/07/24 06:00 [entrez]
PHST- 2019/07/25 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2019.01529 [doi]
PST - epublish
SO  - Front Immunol. 2019 Jul 4;10:1529. doi: 10.3389/fimmu.2019.01529. eCollection 
      2019.